LU90935I2 - Azopt-brinzolamide - Google Patents

Azopt-brinzolamide

Info

Publication number
LU90935I2
LU90935I2 LU90935C LU90935C LU90935I2 LU 90935 I2 LU90935 I2 LU 90935I2 LU 90935 C LU90935 C LU 90935C LU 90935 C LU90935 C LU 90935C LU 90935 I2 LU90935 I2 LU 90935I2
Authority
LU
Luxembourg
Prior art keywords
azopt
brinzolamide
disclosed
intraocular pressure
controlling intraocular
Prior art date
Application number
LU90935C
Other languages
English (en)
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of LU90935I2 publication Critical patent/LU90935I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU90935C 1990-04-09 2002-07-05 Azopt-brinzolamide LU90935I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50673090A 1990-04-09 1990-04-09
US07/618,765 US5153192A (en) 1990-04-09 1990-11-27 Thiophene sulfonamides useful as carbonic anhydrase inhibitors
PCT/US1991/002262 WO1991015486A1 (fr) 1990-04-09 1991-04-03 Sulfamides de thiophene utiles en tant qu'inhibiteurs d'anhydrase carbonique

Publications (1)

Publication Number Publication Date
LU90935I2 true LU90935I2 (en) 2002-09-05

Family

ID=27055558

Family Applications (2)

Application Number Title Priority Date Filing Date
LU90935C LU90935I2 (en) 1990-04-09 2002-07-05 Azopt-brinzolamide
LU91555C LU91555I2 (fr) 1990-04-09 2009-04-22 "Brinzolamide et timolol optionnellement sous de sels pharmaceutiquement acceptables te que la combination du produit brinzolamide/timolol maléate (AZARGA)"

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91555C LU91555I2 (fr) 1990-04-09 2009-04-22 "Brinzolamide et timolol optionnellement sous de sels pharmaceutiquement acceptables te que la combination du produit brinzolamide/timolol maléate (AZARGA)"

Country Status (19)

Country Link
US (2) US5153192A (fr)
EP (1) EP0527801B1 (fr)
JP (1) JP2562394B2 (fr)
KR (1) KR100196414B1 (fr)
AT (1) ATE221527T1 (fr)
AU (1) AU655924B2 (fr)
BR (1) BR9106330A (fr)
CA (1) CA2080223C (fr)
DE (3) DE122009000026I1 (fr)
DK (1) DK0527801T3 (fr)
ES (1) ES2180530T3 (fr)
FI (2) FI924553L (fr)
IL (1) IL97800A (fr)
LU (2) LU90935I2 (fr)
NL (2) NL300098I2 (fr)
NO (1) NO923948L (fr)
NZ (1) NZ237754A (fr)
WO (1) WO1991015486A1 (fr)
ZA (1) ZA912580B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585377A (en) * 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
FR2662439B1 (fr) * 1990-05-23 1993-11-19 Rhone Poulenc Chimie Reactif et procede de perfluoroalkylation de substrats nucleophiles par les perfluoroalcanesulfinates de sodium en milieu oxydant.
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
WO1993016701A2 (fr) * 1992-02-21 1993-09-02 Alcon Laboratories, Inc. Compositions antiglaucome a usage local comprenant des inhibiteurs d'anhydrase carbonique et de beta-bloquants
US5276025A (en) * 1992-09-09 1994-01-04 Merck & Co., Inc. Heterobicyclic sulfonamides
US5308842A (en) * 1992-09-09 1994-05-03 Merck & Co., Inc. Tricyclic derivatives of the thienodiazocine and thienothiadiazocine classes of compounds
AU3722793A (en) * 1992-09-17 1994-04-12 Alcon Laboratories, Inc. Topical carbonic anhydrase inhibitor composition
US5344929A (en) * 1993-02-18 1994-09-06 Alcon Laboratories, Inc. Preparation of carbonic anhydrase inhibitors
US5538966A (en) * 1994-01-21 1996-07-23 Alcon Laboratories, Inc. Carbonic anhydrase inhibitors
WO1995019981A1 (fr) * 1994-01-21 1995-07-27 Alcon Laboratories, Inc. Procede de preparation de derives du thienothiazine sulfonamide, intermediaires de preparation, et utilisation comme inhibiteurs d'anhydrases carboniques
US5646142A (en) * 1994-07-08 1997-07-08 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5464831A (en) * 1994-09-09 1995-11-07 Alcon Laboratories, Inc. Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5510347A (en) * 1994-09-09 1996-04-23 Alcon Laboratories, Inc. Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors
US5470973A (en) * 1994-10-03 1995-11-28 Alcon Laboratories, Inc. Synthesis of sulfonamide intermediates
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
AU2998995A (en) * 1995-07-12 1997-02-10 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
EP1057486A1 (fr) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. L'utilisation d'une combinaison de produits pharmacologiques dans le traitement du glaucome
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
ES2199348T4 (es) * 1996-02-26 2010-10-19 ADVANCED RESEARCH & TECHNOLOGY INSTITUTE Uso de inhibidores de carbonico anhidrasa para el tratamiento del edema macular.
US5900427A (en) * 1996-05-03 1999-05-04 Wisconsin Alumni Research Foundation N-heteroarenesulfonyl-protected amino acid reagents for peptide synthesis
AUPO227896A0 (en) * 1996-09-13 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Novel compounds and their preparation
WO1999032123A1 (fr) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Utilisation de brinzolamide pour prevenir la perte du champ visuel
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
WO1999044603A1 (fr) * 1998-03-06 1999-09-10 Sponsel William E Traitement de troubles maculaires et composition appropriee
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6960579B1 (en) * 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
WO2001052876A1 (fr) * 2000-01-18 2001-07-26 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
JP2004538240A (ja) * 2000-03-31 2004-12-24 パーデュー・リサーチ・ファウンデーション ホスホラミデートおよびそのための方法
AU2001217709B2 (en) * 2000-11-16 2005-10-13 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003216547A1 (en) * 2002-03-15 2003-09-29 Merck And Co., Inc. Compositions and methods for treating glaucoma and ocular hypertension
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
CA2488802A1 (fr) * 2002-06-14 2003-12-24 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
JP2005538061A (ja) * 2002-06-17 2005-12-15 メルク　エンド　カムパニー　インコーポレーテッド 新規ｍａｘｉ−ｋチャネルブロッカー、その使用方法および製造方法
EP1515722A4 (fr) * 2002-06-17 2006-06-21 Merck & Co Inc Compositions ophtalmiques destinees a traiter l'hypertension oculaire
AU2003247533B2 (en) * 2002-06-17 2008-09-18 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
CA2495917A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
AU2003275840A1 (en) * 2002-10-25 2004-05-13 Merck Frosst Canada Ltd 2-pyrrolidones as EP4 receptor agonists
KR100503618B1 (ko) * 2002-11-07 2005-07-26 안헌상 케이크용 장식용품
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
WO2004087051A2 (fr) * 2003-03-27 2004-10-14 Merck & Co., Inc. Compositions ophtalmiques pour traiter une hypertension oculaire
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
KR100537781B1 (ko) * 2004-06-02 2005-12-20 안헌상 케이크 장식용품의 제조방법 및 그 물품
KR101333990B1 (ko) 2005-07-12 2013-11-27 코와 가부시키가이샤 녹내장을 예방 또는 치료하는 약제
JP4831668B2 (ja) * 2006-02-16 2011-12-07 独立行政法人産業技術総合研究所 新規なチアジノインドール化合物およびその製造方法
LT5504B (lt) 2006-08-02 2008-06-25 Biotechnologijos Institutas Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti
JP5301465B2 (ja) 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
WO2008120099A1 (fr) * 2007-03-30 2008-10-09 Pfizer Inc. Dérivé de thiéno [3, 2-e] [1, 2] thiazine en tant qu'inhibiteur d'anhydrase carbonique
EP1985618A1 (fr) * 2007-04-27 2008-10-29 Duke Chem, S. A. Procédé de préparation de brinzolamide et intermédiaires correspondants
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
ITMI20081084A1 (it) * 2008-06-16 2009-12-17 Phf Sa Processo per la preparazione di brinzolamide
US8332007B2 (en) * 2009-01-12 2012-12-11 The Board Of Trustees Of The University Of Illinois Quantitative three-dimensional mapping of oxygen tension
CN102414192A (zh) * 2009-03-13 2012-04-11 Azad药物成分股份公司 制备布林唑胺的方法
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2348026A1 (fr) * 2009-12-22 2011-07-27 Duke Chem, S. A. Procédé de préparation de brinzolamide et des intermédiares
EP2394637A1 (fr) 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Procédé pour l'obtention de suspensions stériles de brinzolamide
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
WO2012053011A2 (fr) 2010-10-18 2012-04-26 Usv Limited Compositions ophthalmiques comprenant de la brinzolamide
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
JP5836851B2 (ja) * 2012-03-12 2015-12-24 株式会社トクヤマ ブリンゾラミドの製造方法
EP2638909A1 (fr) 2012-03-15 2013-09-18 Azad Pharmaceutical Ingredients AG Procédé de préparation stérile brinzolamide
JP5881514B2 (ja) * 2012-04-09 2016-03-09 株式会社トクヤマ アミン誘導体の製造方法
JP5914246B2 (ja) * 2012-08-10 2016-05-11 株式会社トクヤマ ブリンゾラミドの精製方法
CN102936236A (zh) * 2012-11-13 2013-02-20 江苏吉贝尔药业有限公司 一种布林佐胺中间体(3-乙酰基-5-氯-2-(苄基巯基)噻酚)的制备方法
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
CA2924562A1 (fr) 2013-10-17 2015-04-23 Sentiss Pharma Private Limited Formulation pharmaceutique ophtalmique sans conservateur
US9820991B2 (en) 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
US10463674B2 (en) 2013-11-08 2019-11-05 Sentiss Pharma Private Limited Process for manufacturing sterile ophthalmic pharmaceutical suspensions
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
EP3209331B1 (fr) 2014-10-20 2023-07-12 Sentiss Pharma Private Limited Solution ophtalmique
JP6192878B1 (ja) * 2015-12-10 2017-09-06 千寿製薬株式会社 眼科用医薬製品
US10040804B2 (en) 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019207380A1 (fr) 2018-04-25 2019-10-31 Shilpa Medicare Limited Compositions ophtalmiques de brinzolamide
WO2024236599A1 (fr) 2023-05-16 2024-11-21 Micro Labs Limited Solution ophtalmique de brinzolamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA661731A (en) * 1963-04-23 Farbwerke Hoechst Aktiengesellschaft Vormals Meister Lucius And Bruning Substituted thiophene-3,5-disulfonamides and a process for preparing them
DE1096916B (de) * 1957-12-17 1961-01-12 Hoechst Ag Verfahren zur Herstellung von Thiophen-3, 5-disulfonamiden
GB1516024A (en) * 1977-04-20 1978-06-28 Pfizer Ltd Thiophene-2,5-disulphonamides
US4746745A (en) * 1980-07-09 1988-05-24 Maren Thomas H 1,3,4-thiadiazoline-5-sulfonamides
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4847289A (en) * 1987-06-08 1989-07-11 Merck & Co., Inc. Thiophene sulfonamide antiglaucoma agents
US5093332A (en) * 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents

Also Published As

Publication number Publication date
AU655924B2 (en) 1995-01-19
US5153192A (en) 1992-10-06
DE69133080D1 (de) 2002-09-05
NO923948L (no) 1992-12-08
ES2180530T3 (es) 2003-02-16
ATE221527T1 (de) 2002-08-15
IL97800A (en) 1997-08-14
DK0527801T3 (da) 2002-11-25
NL300098I2 (nl) 2003-01-06
DE69133080T2 (de) 2003-03-27
KR930700490A (ko) 1993-03-15
EP0527801A4 (en) 1993-03-10
EP0527801A1 (fr) 1993-02-24
WO1991015486A1 (fr) 1991-10-17
CA2080223A1 (fr) 1991-10-10
NL300389I1 (nl) 2009-07-01
FI963424A7 (fi) 1996-09-02
NL300098I1 (nl) 2002-11-01
DE10299054I1 (de) 2006-06-08
FI924553A7 (fi) 1992-10-08
DE122009000026I1 (de) 2010-01-28
JP2562394B2 (ja) 1996-12-11
HK1014186A1 (en) 1999-09-24
FI924553A0 (fi) 1992-10-08
IL97800A0 (en) 1992-06-21
JPH05508832A (ja) 1993-12-09
FI924553L (fi) 1992-10-08
EP0527801B1 (fr) 2002-07-31
AU7746791A (en) 1991-10-30
CA2080223C (fr) 2000-11-07
NO923948D0 (no) 1992-10-09
ZA912580B (en) 1992-01-29
FI963424L (fi) 1996-09-02
NZ237754A (en) 1992-08-26
KR100196414B1 (ko) 1999-06-15
BR9106330A (pt) 1993-04-20
LU91555I2 (fr) 2009-06-22
US5240923A (en) 1993-08-31
FI963424A0 (fi) 1996-09-02

Similar Documents

Publication Publication Date Title
LU90935I2 (en) Azopt-brinzolamide
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
UA32512C2 (uk) Похідні ксантину, спосіб їх одержання, та фармацевтична композиція
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU7317387A (en) Use of tetrahydrocortisol in glaucoma therapy
IL99393A0 (en) Thiazolidine derivatives,methods for the preparation thereof and pharmaceutical composition containing the same
GR3006815T3 (fr)
IL106521A0 (en) Pharmaceutical composition for the treatment or prevention of elevated intraocular pressure
EP0387821A3 (fr) 2-Alkyl-4-arylméthylaminoquinoléines, leur utilisation et médicaments les contenant
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
AU7125991A (en) Novel antiulcer substance
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
NZ234369A (en) 6-(naphthalenylethyl)-4-hydroxy-pyran-2-one derivatives and the 3,5-dihydroxyheptanoates; pharmaceutical compositions
EP0147707A3 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
IL89901A0 (en) Strobilurine derivatives
GR3005231T3 (fr)
IE900460L (en) Pharmaceutical composition
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
GR910100379A (en) Stabilizing valve for liquid administration
AU8744691A (en) N-((2-thenoylmercapto-3-methyl)-butanoyl)-homocysteine thiolactone, a process for the preparation thereof and pharmaceutical compositions containing it
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili
IL106961A0 (en) Pharmaceutical compositions for treatment of the eyes
IL94194A0 (en) Pharmaceutical compositions containing piperidinyl-benzocycloheptathiophenone derivatives and methods for the use thereof